Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
吉非替尼(一种 EGFR 酪氨酸激酶抑制剂)联合安罗替尼(一种多激酶抑制剂)治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌(FL-ALTER):一项多中心 III 期试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-024-01927-9
Zhou, Hua-Qiang; Zhang, Ya-Xiong; Chen, Gang; Yu, Qi-Tao; Zhang, Hua; Wu, Guo-Wu; Wu, Di; Lin, Ying-Cheng; Zhu, Jun-Fei; Chen, Jian-Hua; Hu, Xiao-Hua; Lan, Bin; Zhou, Ze-Qiang; Lin, Hai-Feng; Wang, Zi-Bing; Lei, Xiao-Lin; Pan, Suo-Ming; Chen, Li-Ming; Zhang, Jian; Kong, Tian-Dong; Yao, Ji-Cheng; Zheng, Xin; Li, Feng; Zhang, Li; Fang, Wen-Feng